Stemtech Stock Performance
| STEK Stock | USD 0.05 0.0001 0.20% |
On a scale of 0 to 100, Stemtech holds a performance score of 4. The entity has a beta of 2.09, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Stemtech will likely underperform. Please check Stemtech's total risk alpha and the relationship between the potential upside and day typical price , to make a quick decision on whether Stemtech's existing price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Stemtech are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Stemtech disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 133.1 K | |
| Free Cash Flow | -1.9 M |
Stemtech |
Stemtech Relative Risk vs. Return Landscape
If you would invest 4.80 in Stemtech on September 12, 2024 and sell it today you would earn a total of 0.21 from holding Stemtech or generate 4.38% return on investment over 90 days. Stemtech is currently generating 0.9394% in daily expected returns and assumes 16.4655% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Stemtech, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Stemtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stemtech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Stemtech, and traders can use it to determine the average amount a Stemtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0571
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | STEK | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 16.47 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.94 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Stemtech is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Stemtech by adding it to a well-diversified portfolio.
Stemtech Fundamentals Growth
Stemtech OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Stemtech, and Stemtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stemtech OTC Stock performance.
| Return On Asset | -0.75 | |||
| Profit Margin | (1.85) % | |||
| Operating Margin | (1.34) % | |||
| Current Valuation | 8.79 M | |||
| Shares Outstanding | 48.63 M | |||
| Price To Sales | 1.54 X | |||
| Revenue | 4.32 M | |||
| EBITDA | 1.58 M | |||
| Cash And Equivalents | 399.73 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 219.47 K | |||
| Book Value Per Share | (0.08) X | |||
| Cash Flow From Operations | (1.91 M) | |||
| Earnings Per Share | 0.10 X | |||
| Total Asset | 5.72 M | |||
About Stemtech Performance
By examining Stemtech's fundamental ratios, stakeholders can obtain critical insights into Stemtech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stemtech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Stemtech performance evaluation
Checking the ongoing alerts about Stemtech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Stemtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Stemtech is way too risky over 90 days horizon | |
| Stemtech has some characteristics of a very speculative penny stock | |
| Stemtech appears to be risky and price may revert if volatility continues | |
| Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 64.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Stemtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stemtech's stock is overvalued or undervalued compared to its peers.
- Examining Stemtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Stemtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stemtech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Stemtech's otc stock. These opinions can provide insight into Stemtech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.